
Last update at 2026-01-30 15:49:52
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Income before tax | 10160.90M | 7460.70M | 8240.10M | 7728.90M | 6687.20M |
| Net income | 7676.00M | 5513.30M | 6239.30M | 6125.60M | 4976.10M |
| Total Revenue | 22813.50M | 21931.70M | 24247.60M | 26105.50M | 22384.30M |
| Gross Profit | 14655.40M | 13948.90M | 15510.90M | 16625.20M | 14406.90M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Total assets | 49111.10M | 42287.80M | 40007.30M | 39005.10M | 32659.00M |
| Intangible assets | 243.10M | 342.70M | 442.30M | 945.50M | 1448.70M |
| Other current assets | 428.60M | 1209.90M | 414.40M | 17.10M | 1491.60M |
| Deferred long term liab | - | - | - | - | - |
| Non current assets other | - | - | - | - | - |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Change in Cash | 3830.70M | 754.00M | -261.60M | -884.50M | -16125.80M |
| Operating Cash | 6597.50M | 2568.40M | 3556.80M | 6670.80M | 4273.30M |
| Free Cash Flow | 6316.00M | 2379.10M | 2907.00M | 6517.70M | 4096.30M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change | Price | Market Cap (M) | P/E Ratio |
|---|---|---|---|---|
| PFIZER Pfizer Limited |
-35.60 -0.77% | 4563.60 | 222237.90 | 26.50 |
| GLAXO GlaxoSmithKline Pharmaceuticals Limited |
-22.40 -0.92% | 2412.90 | 406354.23 | 42.58 |
| SANOFICONR SANOFI CONS HEALTHC IND L |
-97.90 -2.23% | 4291.00 | 101612.67 | 46.61 |
| SANOFI Sanofi India Limited |
22.40 0.56% | 4037.60 | 95811.08 | 26.88 |
| MARKSANS Marksans Pharma Limited |
-2.46 -1.37% | 177.58 | 81052.87 | 23.02 |
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.
The Capital, 1802/1901, Mumbai, India, 400051
| Name | Title | Year Born |
|---|---|---|
| Mr. Sridhar Subramaniam | CEO, MD, Lead of Essential Health Portfolio & Director | 1968 |
| Mr. Milind Anil Patil | CFO, Exec. Director of Fin. & Whole-time Director | 1964 |
| Mr. Samir Salauddin Kazi | Exec. Director of Legal & Exec. Director | 1975 |
| Mr. Prajeet Nair C.S. | Compliance Officer & Company Sec. | NA |
| Mr. Sharad Goswami | Sr. Director of Policy & Public Affairs | NA |
| Ms. Shilpi Singh | Director of People Experience | NA |
| Ms. Meenakshi Nevatia | MD, CEO & Director | 1970 |
| Mr. Prajeet Nair C.S. | Director of Corporate Services, Company Secretary & Compliance Officer | NA |
| Mr. Pazhania Pillai Rengan | Whole-Time Director & Executive Director of Plant Operations | 1979 |
| Mr. Anil Pattanshetty | Senior Director of Business Operations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data ("EODHD") on an 'as is' basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.